MX2017005663A - Tetrahidropiranos sustituidos y metodo de uso. - Google Patents
Tetrahidropiranos sustituidos y metodo de uso.Info
- Publication number
- MX2017005663A MX2017005663A MX2017005663A MX2017005663A MX2017005663A MX 2017005663 A MX2017005663 A MX 2017005663A MX 2017005663 A MX2017005663 A MX 2017005663A MX 2017005663 A MX2017005663 A MX 2017005663A MX 2017005663 A MX2017005663 A MX 2017005663A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- formula
- methods
- substituted tetrahydropyrans
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Los compuestos de la fórmula (I): (ver Fórmula) y las sales farmacéuticamente aceptables o las formas radiomarcadas de los mismos, en donde R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12 y m son como se definen en la memoria descriptiva, son útiles en el tratamiento de las afecciones o los trastornos que sean prevenidos o mitigados por la proteína reguladora de la conductancia transmembrana de la fibrosis quística (CFTR). Se describen los métodos para la elaboración de los compuestos. También se describen composiciones farmacéuticas de los compuestos de la fórmula (I) y los métodos para utilizar estos compuestos y composiciones.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462073586P | 2014-10-31 | 2014-10-31 | |
PCT/US2015/058043 WO2016069891A1 (en) | 2014-10-31 | 2015-10-29 | Substituted tetrahydropyrans and method of use |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017005663A true MX2017005663A (es) | 2018-03-01 |
Family
ID=55851906
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017005663A MX2017005663A (es) | 2014-10-31 | 2015-10-29 | Tetrahidropiranos sustituidos y metodo de uso. |
Country Status (10)
Country | Link |
---|---|
US (1) | US9567322B2 (es) |
EP (1) | EP3212184B1 (es) |
JP (1) | JP6615213B2 (es) |
CN (1) | CN107427490A (es) |
AU (1) | AU2015339196A1 (es) |
BR (1) | BR112017009194A2 (es) |
CA (1) | CA2966023A1 (es) |
MX (1) | MX2017005663A (es) |
TW (1) | TW201625599A (es) |
WO (1) | WO2016069891A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5409010B2 (ja) | 2005-12-28 | 2014-02-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | N−[2,4−ビス(1,1−ジメチルエチル)−5−ヒドロキシフェニル]−1,4−ジヒドロ−4−オキソキノリン−3−カルボキサミドの固体形態 |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
KR20130056244A (ko) | 2010-04-22 | 2013-05-29 | 버텍스 파마슈티칼스 인코포레이티드 | 시클로알킬카르복스아미도-인돌 화합물의 제조 방법 |
PL3925607T3 (pl) | 2014-04-15 | 2023-10-30 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa |
US9840513B2 (en) * | 2015-07-16 | 2017-12-12 | Abbvie S.Á.R.L. | Substituted tricyclics and method of use |
JP2018530557A (ja) | 2015-10-09 | 2018-10-18 | アッヴィ・エス・ア・エール・エル | 置換ピラゾロ[3,4−b]ピリジン−6−カルボン酸およびこの使用 |
AU2016333907A1 (en) | 2015-10-09 | 2018-04-12 | AbbVie S.à.r.l. | Novel compounds for treatment of cystic fibrosis |
CA3001096A1 (en) | 2015-10-09 | 2017-04-13 | Abbvie S.A.R.L. | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use |
US10138227B2 (en) | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
US10399940B2 (en) | 2016-10-07 | 2019-09-03 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
US9981910B2 (en) | 2016-10-07 | 2018-05-29 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
EP3558982A1 (en) | 2016-12-20 | 2019-10-30 | AbbVie S.À.R.L. | Deuterated cftr modulators and methods of use |
TW201831471A (zh) | 2017-02-24 | 2018-09-01 | 盧森堡商艾伯維公司 | 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法 |
US10988454B2 (en) | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
WO2019193062A1 (en) | 2018-04-03 | 2019-10-10 | Abbvie S.Á.R.L | Substituted pyrrolidines and their use |
CN110483457A (zh) * | 2018-05-14 | 2019-11-22 | 上海迈法生物科技有限公司 | 4-氨基四氢吡喃的一锅法合成工艺 |
US11345691B2 (en) | 2019-06-03 | 2022-05-31 | AbbVie Global Enterprises Ltd. | Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
TW202115014A (zh) | 2019-07-12 | 2021-04-16 | 美商奧佛麥德公司 | 用於治療囊腫纖維化之化合物 |
WO2022150174A1 (en) | 2021-01-06 | 2022-07-14 | AbbVie Global Enterprises Ltd. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
US20220213041A1 (en) | 2021-01-06 | 2022-07-07 | AbbVie Global Enterprises Ltd. | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005035514A2 (en) * | 2003-10-08 | 2005-04-21 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups |
AU2005251745A1 (en) | 2004-06-04 | 2005-12-22 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
CN101006076B (zh) | 2004-06-24 | 2010-09-29 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的调控剂 |
ES2548292T3 (es) | 2007-05-25 | 2015-10-15 | Vertex Pharmaceuticals Incorporated | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
TWI439462B (zh) | 2007-12-10 | 2014-06-01 | Novartis Ag | 作為enac阻抑劑之螺環胍化合物 |
CN101925603B (zh) | 2007-12-13 | 2013-12-04 | 沃泰克斯药物股份有限公司 | 囊性纤维化跨膜通道调节因子的调节剂 |
WO2009084034A2 (en) * | 2007-12-18 | 2009-07-09 | Glenmark Pharmaceuticals, S. A. | Chromane derivatives as trpv3 modulators |
SI2615085T1 (sl) * | 2008-03-31 | 2015-11-30 | Vertex Pharmaceuticals Incorporated | Piridilni derivati kot cftr-modulatorji |
EP2326622A1 (en) * | 2008-07-28 | 2011-06-01 | Gilead Sciences, Inc. | Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds |
PL2358680T3 (pl) | 2008-10-23 | 2013-08-30 | Vertex Pharma | Stałe postacie N-(4-(7-azabicyklo[2.2.1]heptan-7-ylo)-2-(trifluorometylo)fenylo)-4-okso-5-(trifluorometylo)-1,4-dihydrochinolino-3-karboksyamidu |
JP5699090B2 (ja) | 2008-12-30 | 2015-04-08 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | 嚢胞性線維症膜コンダクタンス調節因子のモジュレーター |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
CA2795748C (en) | 2010-04-07 | 2020-12-08 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
JP5886433B2 (ja) | 2011-09-16 | 2016-03-16 | ノバルティス アーゲー | 嚢胞性線維症処置のためのヘテロ環式化合物 |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
EP2755652B1 (en) | 2011-09-16 | 2021-06-02 | Novartis AG | N-substituted heterocyclyl carboxamides |
US9771327B2 (en) | 2013-03-13 | 2017-09-26 | Flatley Discovery Lab, Llc | Compounds and methods for the treatment of cystic fibrosis |
US9783529B2 (en) | 2013-03-13 | 2017-10-10 | Flatley Discovery Lab, Llc | Pyridazinone compounds and methods for the treatment of cystic fibrosis |
US9790219B2 (en) | 2014-03-13 | 2017-10-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
CA2942387A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr actvity |
-
2015
- 2015-10-29 CN CN201580071658.4A patent/CN107427490A/zh active Pending
- 2015-10-29 CA CA2966023A patent/CA2966023A1/en not_active Abandoned
- 2015-10-29 EP EP15854248.0A patent/EP3212184B1/en active Active
- 2015-10-29 JP JP2017542799A patent/JP6615213B2/ja not_active Expired - Fee Related
- 2015-10-29 US US14/926,727 patent/US9567322B2/en active Active
- 2015-10-29 MX MX2017005663A patent/MX2017005663A/es unknown
- 2015-10-29 WO PCT/US2015/058043 patent/WO2016069891A1/en active Application Filing
- 2015-10-29 BR BR112017009194A patent/BR112017009194A2/pt not_active Application Discontinuation
- 2015-10-29 AU AU2015339196A patent/AU2015339196A1/en not_active Abandoned
- 2015-10-30 TW TW104135959A patent/TW201625599A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP6615213B2 (ja) | 2019-12-04 |
AU2015339196A1 (en) | 2017-05-11 |
US9567322B2 (en) | 2017-02-14 |
JP2017533277A (ja) | 2017-11-09 |
CA2966023A1 (en) | 2016-05-06 |
EP3212184A4 (en) | 2018-07-04 |
EP3212184B1 (en) | 2020-04-01 |
BR112017009194A2 (pt) | 2017-12-26 |
US20160122331A1 (en) | 2016-05-05 |
EP3212184A1 (en) | 2017-09-06 |
WO2016069891A1 (en) | 2016-05-06 |
TW201625599A (zh) | 2016-07-16 |
CN107427490A (zh) | 2017-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017005663A (es) | Tetrahidropiranos sustituidos y metodo de uso. | |
GEP20217329B (en) | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | |
MX2016010056A (es) | 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso. | |
MX2021009673A (es) | Moduladores de ror-gamma. | |
SG10201902963PA (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
PH12016502378A1 (en) | Substituted dihydroisoquinolinone compounds | |
MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
MY190429A (en) | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors | |
NZ710270A (en) | Pyridone amides as modulators of sodium channels | |
MY193728A (en) | Muscarinic receptor agonists | |
MX2015009270A (es) | Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk). | |
TW201613864A (en) | Novel compounds | |
MD20170011A2 (ro) | Compuşi imidazopiridazinici | |
MX2016009581A (es) | Derivados de 6-fenil- o 6-(piridin-3-il) indazol y metodos de uso. | |
NZ734400A (en) | Amide compounds as 5-ht4 receptor agonists | |
PH12017500595A1 (en) | Aldosterone synthase inhibitors | |
NZ737892A (en) | Muscarinic m1 receptor positive allosteric modulators | |
MX2016009621A (es) | Derivados de fur0-3-carboxamida y metodos de uso. | |
EA201691252A1 (ru) | Соединения индазола в качестве агонистов 5-ht-рецептора | |
MX2017003458A (es) | Indazol ureas y metodo de uso. | |
PH12017501134A1 (en) | Fumagillol derivatives | |
CA2914263C (en) | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors |